Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

PURPOSE: The addition of bevacizumab to cytotoxic chemotherapy has demonstrated a progression free survival (PFS) benefit in the first line and second line treatment of advanced or metastatic breast cancer (MBC). However, the addition of bevacizumab to capecitabine in heavily pretreated MBC patients...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jubb, Adrian M., Miller, Kathy D., Rugo, Hope S., Harris, Adrian L., Chen, Dafeng, Reimann, James D., Cobleigh, Melody A., Schmidt, Maike, Langmuir, Virginia K., Hillan, Kenneth J., Chen, Daniel S., Koeppen, Hartmut
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3023787/
https://ncbi.nlm.nih.gov/pubmed/21224365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1791
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars